Skip to main content

Analysis of the relationship between GLUT family in the progression and immune infiltration of head and neck squamous carcinoma


Head and neck squamous cell carcinoma (HNSCC) causes much health and economic burden, and the therapeutic results must be improved. Glucose metabolism is an essential component of tumor metabolism and is instrumental in its development. Glucose transporter types (GLUTs) can uptake glucose from the extracellular matrix (ECM), regulating cellular metabolism in several cancers. However, the function of different GLUT proteins in HNSCC remains unclear. To clarify the role of GLUTs in HNSCC, several open-access online databases (Oncomine, GEPIA, Kaplan–Meier, cBioPortal, GeneMANIA, and TIMER) were used to evaluate the differential expression, clinical significance, genetic alteration, and relative immune cell infiltration. The expression of GLUTs was detected in clinical patient samples by immunohistochemistry. The mRNA level of SLC2A1/3 significantly increased in HNSCC, while SLC2A4 reduced. SLC2A3 was related to the advanced clinical stage and short overall survival (OS) in HNSCC. Also, higher SLC2A1/2 mRNA expression was related to shorter OS in HNSCC patients. The expression of GLUTs was related to diverse immune cells, including B cells, CD4+ T cells, CD8+ T cells, dendritic cells (DCs), macrophages, and Treg cells in HNSCC. Moreover, the high expression of GLUTs was demonstrated by immunohistochemistry in patient tissues. GLUTs might have a potential role in HNSCC's progression and development. Therefore, the current findings might offer a novel perception for selecting GLUT family prognostic markers and treatment for HNSCC patients.

Impact statement

Herein, we provided evidence for the relationship between GLUTs and HNSCC using bioinformatics approaches. The expression of GLUTs was significantly associated with the clinical cancer stage and short overall survival (OS) in HNSCC patients. Also, the expression of GLUTs was significantly correlated with the infiltration of diverse immune cells. We also conducted immunohistochemistry to test the expression of GLUTs in patient tissues. Our findings might provide novel insights for selecting GLUT family prognostic markers in HNSCC. These findings might also help develop new personalized treatments for HNSCC by monitoring the immune microenvironment, which might play a significant role in devising personalized therapeutic approaches for HNSCC patients.


Head and neck squamous cell carcinoma (HNSCC) causes much health and economic burden, accounting for 3% of all malignancies [1, 2]. HNSCC can occur on several sites, mainly in the oral cavity, larynx, and hypopharynx. It is associated with lifestyle risk factors, including the most common alcohol and tobacco [3,4,5]. The surgery section is the most common therapy for HNSCC. However, the dysfunctions after surgery are inconvenient to patients. Many studies have shown that metabolic reprogramming in HNSCC and glucose metabolism is critical in oncogenesis [6], the most common component of energy metabolism, and its potential therapeutic value should be explored.

As a glucose membrane transporter, the glucose transporter type (GLUT, also known as SLC2A) can uptake glucose from the extracellular matrix (ECM) and regulate cellular metabolism in several cancers [7]. Many GLUT family proteins are oncogenes involved in the progression of various tumors, such as bladder and prostate cancers [8]. The prognostic and immunotherapeutic roles of SLC2A have been explored in numerous cancers. However, studies on GLUT family proteins and their relationship are rare.

Although GLUTs can be categorized into three classes according to the gene sequence similarity and substrate specificity: Class 1 (GLUTs 1–4 and 14), Class 2 (GLUTs 5, 7, 9, and 11), and Class 3 (GLUTs 6, 8, 10, 12, and 13/HMIT), all in all, GLUTs 1–4 were the most famous and investigated members in field of cancer research [7], and play a predominant role in maintaining cellular glucose uptake and functional metabolic homeostasis during carcinogenesis. Therefore, the expression patterns and prognostic roles of these GLUT members, GLUTs 1–4, in tumors were investigated in this study. GLUT-1 expression has been associated with therapeutic resistance in multiple malignancies, including in HNSCC, owing to the effects on DNA repair [9]. But the GLUT2 was detected in both malignant and normal epithelial cells. Also, the GLUT3 was found to be highly expressed in the tumor site, compared to the healthy tissue [10]. The GLUT4 expression is quite prevalent expressed in the HNSCC, but the studies in patient is rare [11]. Hence, to analyze the connection between GLUT 1,2,3,4 and the immune infiltration of HNSCC, we used various databases (Oncomine, GEPIA, Kaplan–Meier, cBioPortal, GeneMANIA, and TIMER) and methods to determine the potential oncogenic values and immune infiltration of distinct GLUT family members in HNSCC patients. GLUTs had differential expression in tumor and healthy tissues and affected immunity cells in tumor tissues. Then, we used immunohistochemistry (IHC) to demonstrate their expression in HNSCC tissues.

Materials and methods

Ethics approval and consent to participate

Ethical approval for this study including tumor biopsy collection was obtained from the Research Ethics Committee of Nanjing Stomatology Hospital (No.2019NL-029(KS)) and informed consent was obtained from the patients (Written form). The study was performed in accordance with the Declaration of Helsinki.

Differential mRNA levels

We used publicly available data in Oncomine ( to determine the mRNA levels of GLUT (encoded as SLC2A) [12]. During the analysis, the data type was mRNA, and the cut-off p-value and fold change (FC) were 0.01 and 1:5, respectively, with a gene rank of 10%.

Gene expression analysis

To compare normal and tumor tissues and the pathological stages of HNSCC, we used Gene Expression Profiling Interactive Analysis (GEPIA) to evaluate the expression variance of GLUTs ( [13]. In this case, the Student’s t-test was used.

Kaplan–Meier (K-M) plotter

The relationship of GLUTs expression with the survival of HNSCC patients was accessed with the K-M plotter ( [14]. The K-M plotter web page shows information about the patients, such as the number-at-risk cases, mRNA expression levels, hazard ratios (HRs), 95% confidence intervals (CIs), and p-values. A p < 0.05 was considered statistically significant. Figures were obtained using online tools.

Cancer genomics analysis

The genetic change and the network analysis of the GLUT family in HNSCC were obtained from cBioPortal (, an open-access platform to explore and visualize multidimensional cancer genomic data.

Predictive value of GLUTs

We used GeneMANIA to weigh the predictive value of GLUTs ( [15].

Protein–protein interaction (PPI) network

Also, we applied STRING ( to construct a PPI network to integrate the distinct expressions of GLUTs and their possible interactions [16].

Immune cell infiltration analysis

GLUTs were selected as inputs in the “Gene module,” and scatterplots were generated to visualize the correlation of GLUT expression with immune infiltration levels in HNSCC using TIMER ( [17].

IHC analysis

Ethical approval for this study, including tumor tissue collection and patients informed consent was obtained in accordance with the guidelines and policies of the Research Ethics Committee of Nanjing Stomatology Hospital. The tissue samples from the patients with HNSCC patients were used retrospectively. We collected formalin‑fixed paraffin‑embedded tissue (FFPE) specimens from patients with HNSCC patients to assess the expression of GLUTs. The IHC analysis was performed using routine procedures. First, formalin-fixed, paraffin-embedded tumor samples (4 µm) were deparaffinized. After incubation with primary antibodies (4 °C, overnight), samples were revealed using a liquid diaminobenzidine substrate chromogen system, followed by the hematoxylin staining. Finally, samples were observed.


Differential expression of GLUTs in HNSCC patients

First, we used the Oncomine database to explore the differential mRNA levels of the GLUT family in HNSCC patients (Fig. 1). GLUT (or SLC2A) was differentially expressed between tumor and normal tissues. SLC2A1 and SLC2A3 were remarkably elevated in HNSCC tissue, while SLC2A4 levels decreased. For instance, SLC2A1 was overexpressed in tongue squamous cell carcinoma compared to normal tissue, with an FC of 4.612 (p = 8.20E-8). SLC2A3 was also significantly increased in HNSCC tissues compared to normal tissues with FC of 16.709 (p = 2.39E-23) (Supplementary Table 1).

Fig. 1
figure 1

Different mRNA levels of the SLA2C family in various cancer types

Then, we evaluated the mRNA levels of GLUTs in HNSCC and normal tissues using GEPIA. SLC2A1 and SLC2A3 increased in HNSCC tissues, while SLC2A4 decreased (Fig. 2), consistent with the Oncomine results. The Spearman analysis showed that the expression of SLC2A4 was positively correlated with SLC2A3 but negatively correlated with SLC2A1.

Fig. 2
figure 2

Differential expression of SLC2As in HNSCC from GEPIA (a), and correlations between SLC2A1-4 in HNSCC tissue samples from cBioportal (b)

Next, the relationship between GLUTs and the pathological development stage of HNSCC patients was further analyzed. SLC2A3 was highly variable (p = 0.0059), while the other groups did not differ (Fig. 3). These results suggested that SLC2A3 (GLUT3) might be critical in HNSCC development.

Fig. 3
figure 3

Relationship between SLC2A family and pathological tumor stage in HNSCC patients from GEPIA

Relationship between overall survival (OS) and recurrence-free survival (RFS) and GLUTs expression in HNSCC

To assess the value of differentially expressed GLUTs in the development and progress of HNSCC, we analyzed the relations between GLUTs and clinical results using GEPIA. The OS curves are presented in Fig. 4. HNSCC patients with high GLUT3 levels (p = 0.0031) were significantly associated with short OS. The increase of the GLUT2 was also associated with poor OS (p = 0.02), while high GLUT4 levels may be associated with long OS, but not significantly (p = 0.054).

Fig. 4
figure 4

The OS prognostic value of mRNA levels of distinct SLC2A family members in HNSCC (Kaplan–Meier plotter)

Furthermore, we determined the RFS of HNSCC patients. Unexpectedly, patients with high SCL2A3 and SLC2A4 expression presented decreased RFS, while patients with high SLC2A2 showed increased RFS (Fig. 5). Hence, the prognostic value of SCL2A2 and SCL2A4 for OS was the opposite for RFS.

Fig. 5
figure 5

The RFS prognostic value of mRNA levels of distinct SLC2A family members in HNSCC (Kaplan–Meier plotter)

Genetic alteration, expression, and interaction of GLUTs in HNSCC patients

Further, we analyzed the genetic alterations of GLUTs in HNSCC patients using the cBioPortal online tool. Many variations were found for different HNSCC subtypes, and amplifications were more frequent in HNSCC samples (Fig. 6A, B). SLC2A1, SLC2A2, SLC2A3, and SLC2A4 were altered in 0.8, 12, 1.7, and 1% of the samples, respectively.

Fig. 6
figure 6

Gene mutation and expression analyses of SLC2A in HNSCC. A, B Review of alteration changes in differently expressed SLC2As in HNSCC (data from cBioPortal); C PPI network of differently expressed SLC2A

Furthermore, we constructed a PPI network of the differentially expressed SLC2As to analyze their possible interactions. The GeneMANIA results revealed that the functions of differentially expressed SLC2As and their associated molecules (such as ASPSCR1, STXBP3, HK2, HK3, HK1, SLC2A5, and STX4) were primarily related to hexose transmembrane transporter activity, monosaccharide transmembrane transporter activity, sugar transmembrane transporter activity, carbohydrate homeostasis, and hexose transmembrane transport (Fig. 6C).

Impacts of GLUTs on immune cell infiltration

Immune cell levels are related to the proliferation and progression of cancer cells, impacting their therapeutic effects. Thus, we used the TIMER database to explore the relationship between SLC2A members and relative immune cell infiltration in HNSCC (Fig. 7). SLC2A1 was connected to the infiltration of B and CD4+ T cells but was negatively correlated with macrophages and Treg cells in HNSCC. However, SLC2A2 was not significantly correlated with immune cells in HNSCC patients. SLC2A3 expression was positively related to CD4 + T cells, DCs, and macrophage infiltration. The infiltration of CD4+ T cells and macrophages was also related to SLC2A4 expression in HNSCC patients.

Fig. 7
figure 7

Correlations between the expression of SLC2As and immune cell infiltration (data from TIMER)

GLUT expression in HNSCC tissues

To further explore the GLUTs in tumor tissue, we collected samples from HNSCC patients to detect GLUT1 and GLUT3 expression. GLUT 1 and GLUT3 were highly expressed in tumor tissues, consistent with the above results and previous studies (Fig. 8).

Fig. 8
figure 8

A IHC staining of GLUT1 and GLUT3 in HNSCC tissues (Magnification 20x). B, C Quantitive analysis of (A). ***: p < 0.001. Scale bar = 100 μm


HNSCC is common worldwide, and surgery is the primary treatment. Chemotherapy, radiotherapy, and immunotherapy have gradually attracted more attention [18]. It is now widely accepted that HNSCC has no biomarker to test or diagnose early. Thus, patients are usually diagnosed at advanced stages [2], which poses a great difficulty for the treatment and limits its effectiveness. Therefore, a maker for HNSCC is urgently needed.

Many metabolic changes occur in tumor cells, including glycometabolism and lipid metabolism [19]. Glycometabolism is a complicated process, among which the uptake and transport of glucose are vital. GLUT proteins are essential transporters for the uptake and transportation, comprising the beginning of glycometabolism. The primary way for malignant tumor cells to obtain energy is aerobic glycolysis with glucose as substrate. Blood glucose mainly enters the cell through GLUT. The rapid growth of tumor cells needs a high level of glycolysis. It requires more glucose supply and higher levels of GLUT1 expression on the tumor cell surface, increasing glucose uptake and transport. GLUT1 expression is raised in various malignant tumor cells, including liver, pancreas, breast, esophagus, lung, brain, kidney, skin, ovary, colon, endometrial, and cervical malignant tumors, and the positive expression rate reached 50%. GLUT1 can reflect the essential biological characteristics of benign and malignant tumor proliferation and the degree of hypoxia, invasion, and metastasis and objectively evaluate tumor staging, treatment effects, and patient prognoses.

In the epidermal growth factor (EGF)/epidermal growth factor receptor (EGFR) signal transduction pathway related to tumor invasion, GLUT1 is positively correlated with the expression of the EGFR HER-2 and tumor vascular EGF [20]. GLUT1 is directly related to glucose uptake. According to the principle of abnormal glucose metabolism in tumors, GLUT1 might be used as an evaluation index for tumor treatment effects. For example, GLUT1 overexpression is closely related to the types and energy metabolism of various tumors. Cruz et al. performed rectal biopsies for 81 patients undergoing colonoscopy [21]. Significantly increased GLUT1 expression was found in patients with precancerous lesions in the colon. Yan et al. showed that cancer cells from gastric cancer patients overexpressed SLC2A1, which was positively correlated with the proliferation and metastasis of gastric cancer cells [22]. Additionally, high GLUT1 expression is closely related to the occurrence and prognosis of various malignant tumors such as non-small cell lung cancer, prostate cancer, oral squamous cell carcinoma, ovarian cancer, bladder cancer, pancreatic cancer, and melanoma. It has become one of the crucial clinical detection indicators of cell carcinogenesis. Targeting GLUT1 to develop anti-tumor drugs or diagnostic reagents, blocking the source of nutrients for cells, or disguising drugs as nutrients and supplying them to tumor cells in large quantities has become a focus for the development of anti-tumor reagents.

GLUT2, encoded by the SLC2A2 gene, is the major glucose transporter in the liver, pancreas, gut, kidney, and brain, with low affinity and broad substrates such as galactose, mannose, and fructose, in addition to the transport and delivery of glucose. Meanwhile, GLUT2 expression is related to glucose concentration, insulin secretion, the activity of the autonomic nervous system, and regulation of feeding and body temperature. Therefore, GLUT2 is strongly associated with diabetes [23] and autoimmune diabetes. Besides, GLUT2 is highly expressed in some tumors, including liver [24], breast [25], and gastric cancers [26]. In this study, higher GLUT2 expression is associated with lower OS but higher RFS, which may be explained by the possibility that the poorer OS is attained through other factors but not tumor recurrence.

GLUT3 is mainly expressed in nerve cells and platelets. It is also highly expressed in solid tumors such as non-small cell lung cancer, bladder cancer, oral squamous cell carcinoma [11], and laryngeal cancer [27]. GLUT4 is an insulin-sensitive glucose transporter in skeletal, cardiac, and adipose tissue. It mainly regulates glucose absorption and transport to meet the needs of enhanced glucose metabolism. Chang et al. reported that the increased GLUT4 expression was significantly associated with poor OS and RFS in OSCC, which may promote metastasis through the TRIM24/DDX58 axis [28]. Type 2 diabetes, obesity, and aging are also closely related to impaired GLUT4 expression and function [29].

Herein, we evaluated GLUT expression in HNSCC tissues GLUT1 and GLUT3 were highly expressed in the tumor tissue, consistent with the previous results [30]. Also, we found a relationship between the GLUT family and immunity, corresponding to the previous research involving lung adenocarcinoma, prostate cancer, and breast cancer. Based on our findings, the GLUTs family might be used in HNSCC treatments. On the other hand, the detection of immune-related expression was lacking in this study, and we will remedy this limitation in a follow-up study.


In summary, we analyzed GLUT family members' differential progression and immune infiltration in HNSCC. SLC2A1 and SLC2A3 were significantly increased in HNSCC tissues, while SLC2A4 decreased. SLC2A3 was mainly related to cancer stage development and short OS in HNSCC patients. However, SLC2A1/2 was associated with short OS in HNSCC cancer patients. Furthermore, the expression of GLUTs was significantly related to the infiltration of several immune cells in HNSCC. Our findings might provide a novel strategy to screen a specific prognostic biomarker among GLUTs family members in HNSCC, improving the therapeutic effects in the clinic.

Availability of data and materials

All data generated or analyzed during this study are included in this published article. To be noted, in the section ‘Differential mRNA levels’, since ‘Oncomine’ database have been taken offline on 17 January 2022, so the accession numbers could not be checked. Thus related datasets generated and/or analyzed are not publicly available, but are available from the corresponding author on reasonable request.


  1. Bray F., Ferlay J., Soerjomataram I., Siegel R. L., Torre L. A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;2018(6):394–424.

    Article  Google Scholar 

  2. Xu W, Zou H, Wei Z, Song C, Tang C, Yin X, et al. Rh type C-glycoprotein functions as a novel tumor suppressor gene by inhibiting tumorigenicity and metastasis in head and neck squamous cell carcinoma. Aging. 2019;11(11):3601–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Gupta B, Johnson NW, Kumar N. Global Epidemiology of Head and Neck Cancers: A Continuing Challenge. Oncology. 2016;91(1):13–23.

    Article  PubMed  Google Scholar 

  4. Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019;7(1):184.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Yin X, Yang W, Xie J, Wei Z, Tang C, Song C, et al. HOTTIP Functions as a Key Candidate Biomarker in Head and Neck Squamous Cell Carcinoma by Integrated Bioinformatic Analysis. Biomed Res Int. 2019;2019:5450617.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Kumar D, New J, Vishwakarma V, Joshi R, Enders J, Lin F, et al. Cancer-Associated Fibroblasts Drive Glycolysis in a Targetable Signaling Loop Implicated in Head and Neck Squamous Cell Carcinoma Progression. Cancer Res. 2018;78(14):3769–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Cazzato G, Colagrande A, Cimmino A, Abbatepaolo C, Bellitti E, Romita P, et al. GLUT1, GLUT3 Expression and 18FDG-PET/CT in Human Malignant Melanoma: What Relationship Exists? New Insights and Perspectives. Cells. 2021;10(11):3090.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Xiao H, Wang J, Yan W, Cui Y, Chen Z, Gao X, et al. GLUT1 regulates cell glycolysis and proliferation in prostate cancer. Prostate. 2018;78(2):86–94.

    Article  CAS  PubMed  Google Scholar 

  9. Bao Y-Y, Zhou S-H, Lu Z-J, Fan J, Huang Y-P. Inhibiting GLUT-1 expression and PI3K/Akt signaling using apigenin improves the radiosensitivity of laryngeal carcinoma in vivo. Oncol Rep. 2015;34(4):1805–14.

    Article  CAS  PubMed  Google Scholar 

  10. Estilo CL, O-charoenrat P, Talbot S, Socci ND, Carlson DL, Ghossein R, et al. Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators by oligonucleotide microarray analysis. BMC Cancer. 2009;9:11.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Botha H, Farah CS, Koo K, Cirillo N, McCullough M, Paolini R, et al. The Role of Glucose Transporters in Oral Squamous Cell Carcinoma. Biomolecules. 2021;11(8):1070.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform. Neoplasia. 2004;6(1):1–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Nagy Á, Lánczky A, Menyhárt O, Győrffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018;8(1):9227.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Warde-Farley D., Donaldson S. L., Comes O., Zuberi K., Badrawi R., Chao P., et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38(suppl_2):W214–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2018;47(D1):D607–13.

    Article  PubMed Central  Google Scholar 

  17. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017;77(21):e108–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Lindemann A, Takahashi H, Patel AA, Osman AA, Myers JN. Targeting the DNA Damage Response in OSCC with TP53 Mutations. J Dent Res. 2018;97(6):635–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Liu X, Wang X, Zhang J, Lam EKY, Shin VY, Cheng ASL, et al. Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis. Oncogene. 2010;29(3):442–50.

    Article  CAS  PubMed  Google Scholar 

  20. Majumdar D, Peng XH, Shin DM. The medicinal chemistry of theragnostics, multimodality imaging and applications of nanotechnology in cancer. Curr Top Med Chem. 2010;10(12):1211–26.

    Article  CAS  PubMed  Google Scholar 

  21. Cruz MD, Ledbetter S, Chowdhury S, Tiwari AK, Momi N, Wali RK, et al. Metabolic reprogramming of the premalignant colonic mucosa is an early event in carcinogenesis. Oncotarget. 2017;8(13):20543–57.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Yan S, Wang Y, Chen M, Li G, Fan J. Deregulated SLC2A1 Promotes Tumor Cell Proliferation and Metastasis in Gastric Cancer. Int J Mol Sci. 2015;16(7):16144–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Medina A, Parween S, Ullsten S, Vishnu N, Siu YT, Quach M, et al. Early deficits in insulin secretion, beta cell mass and islet blood perfusion precede onset of autoimmune type 1 diabetes in BioBreeding rats. Diabetologia. 2018;61(4):896–905.

    Article  CAS  PubMed  Google Scholar 

  24. Yamamoto T, Seino Y, Fukumoto H, Koh G, Yano H, Inagaki N, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun. 1990;170(1):223–30.

    Article  CAS  PubMed  Google Scholar 

  25. Zeng K, Ju G, Wang H, Huang J. GLUT1/3/4 as novel biomarkers for the prognosis of human breast cancer. Translational cancer research. 2020;9(4):2363–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Tan ZW, Teo Z, Tan C, Choo CC, Loo WS, Song Y, et al. ANGPTL4 T266M variant is associated with reduced cancer invasiveness. Biochim Biophys Acta, Mol Cell Res. 2017;1864(10):1525–36.

    Article  CAS  Google Scholar 

  27. Starska K, Forma E, Jóźwiak P, Bryś M, Lewy-Trenda I, Brzezińska-Błaszczyk E, et al. Gene and protein expression of glucose transporter 1 and glucose transporter 3 in human laryngeal cancer-the relationship with regulatory hypoxia-inducible factor-1α expression, tumor invasiveness, and patient prognosis. Tumour Biol. 2015;36(4):2309–21.

    Article  CAS  PubMed  Google Scholar 

  28. Chang YC, Chi LH, Chang WM, Su CY, Lin YF, Chen CL, et al. Glucose transporter 4 promotes head and neck squamous cell carcinoma metastasis through the TRIM24-DDX58 axis. J Hematol Oncol. 2017;10(1):11.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Shahwan M, Alhumaydhi F, Ashraf GM, Hasan PMZ, Shamsi A. Role of polyphenols in combating Type 2 Diabetes and insulin resistance. Int J Biol Macromol. 2022;206:567–79.

    Article  CAS  PubMed  Google Scholar 

  30. Zhou JC, Zhang JJ, Zhang W, Ke ZY, Ma LG, Liu M. Expression of GLUT-1 in nasopharyngeal carcinoma and its clinical significance. Eur Rev Med Pharmacol Sci. 2017;21(21):4891–5.

    PubMed  Google Scholar 

Download references


This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations



B.L. participated in the design, interpretation, and analysis of the data and reviewed the manuscript.

Corresponding author

Correspondence to Bing Li.

Ethics declarations

Ethics approval and consent to participate

The present study was approved (approval no. 2019NL-029(KS)) by the Ethics Committee of Nanjing Stomatology Hospital. There was an informed consent waiver from the Ethics Committee of Nanjing Stomatology Hospital. Written informed consent to use the patient data for this study was obtained from all patients.

Competing interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Table S1.

The mRNA levels of GLUTs in different types of HNSCC tissues and normal tissues at transcriptome level. 

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, B. Analysis of the relationship between GLUT family in the progression and immune infiltration of head and neck squamous carcinoma. Diagn Pathol 18, 88 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Head and neck squamous cell carcinoma
  • Biomarker
  • Prognosis
  • Glucose transporter type family
  • Bioinformatics analysis